Werewolf Therapeutics Stock (NASDAQ:HOWL)
Previous Close
$1.34
52W Range
$1.31 - $8.19
50D Avg
$1.64
200D Avg
$2.78
Market Cap
$59.71M
Avg Vol (3M)
$418.56K
Beta
0.41
Div Yield
-
HOWL Company Profile
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
HOWL Performance
Peer Comparison
| Ticker | Company |
|---|---|
| MOLN | Molecular Partners AG |
| CCCC | C4 Therapeutics, Inc. |
| MNOV | MediciNova, Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| STOK | Stoke Therapeutics, Inc. |
| DSGN | Design Therapeutics, Inc. |
| CELC | Celcuity Inc. |
| PASG | Passage Bio, Inc. |
| GLUE | Monte Rosa Therapeutics, Inc. |
| CSBR | Champions Oncology, Inc. |
| ACRV | Acrivon Therapeutics, Inc. Common Stock |
| EWTX | Edgewise Therapeutics, Inc. |
| CGEM | Cullinan Oncology, Inc. |
| VOR | Vor Biopharma Inc. |
| IKNA | Ikena Oncology, Inc. |
| ACET | Adicet Bio, Inc. |
| THRD | Third Harmonic Bio, Inc. |